ACTRN12620000108910已完成1 期
A Phase I Study to evaluate the Pharmacokinetics and the Safety of a Controlled Release Formulation of Octreotide Acetate in Healthy Male Volunteers
Ascil Australia Pty Ltd0 个研究点目标入组 8 人开始时间: 2020年2月6日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 8
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 45 Years（—）
- 性别
- Male
入选标准
- •1.Healthy male subjects, aged 18-45 years (inclusive at the time of informed consent);
- •2.Participants must be in good general health, with no significant medical history, have no clinically significant abnormalities on physical examination at Screening and before administration of the initial dose of study drug;
- •3.Participants must have a minimum body weight of 50kg, and the BMI index (expressed as weight [kg] / height [m2]) must be between 19 and 29 at Screening.
- •4.Participants must have clinical laboratory values within normal range as specified by the testing laboratory, unless deemed not clinically significant by the Investigator;
- •5.Participants must have no relevant dietary restrictions, and be willing to consume standard meals provided during the confinement period;
- •6.Participants engaged in sexual relations with a woman of childbearing potential (WOCBP) must use an acceptable, highly effective, double-barrier contraceptive method from Screening until at least 90 days after dosing. Acceptable methods of contraception include the use of condoms and the use of an effective contraceptive for the female partner that include: oral contraceptive pills (OCPs), long-acting implantable hormones, injectable hormones, a vaginal ring or an intrauterine device (IUD). Participants with same sex partners (abstinence from penile-vaginal intercourse), participants who are surgically sterile (>30 days since vasectomy with no viable sperm), participants whose female partner is post-menopausal or abstinent participants are eligible when this is their preferred and usual lifestyle;
- •7.Participants must not donate sperm for at least 90 days after dosing with the study drug;
- •8.Participants must have the ability and willingness to attend the necessary visits to the Clinical Research Unit (CRU);
- •9.Clinically acceptable blood pressure and pulse rate in supine (systolic blood pressure -SBP- between 90-140 mm Hg/ diastolic blood pressure -DBP- between 50-95 mm Hg / heart rate -HR- between 50-100 bpm). Blood pressure and pulse will be measured after a minimum of 10 minutes of resting.
- •10.Able to understand the nature of the study and comply with all their requirements.
- •11.Participants must be willing and able to provide written informed consent after the nature of the study has been explained and prior to the commencement of any study procedures.
排除标准
- •1.Known thyroid disease, even if effectively euthyroid because of treatment.
- •2.Known hypersensitivity to any component of the study drug;
- •3.Planning for the female partner to become pregnant at any time during the study, including the follow-up period;
- •4.Prior or ongoing medical conditions, medical history, physical findings, or laboratory abnormality that, in the Investigator’s opinion, could adversely affect the safety of the participant;
- •5.Presence of any underlying physical or psychological medical condition that, in the opinion of the Investigator, would make it unlikely that the participant will comply with the protocol or complete the study per protocol;
- •6.Background or clinical evidence of chronic diseases.
- •7.Any surgical or medical condition that could interfere with the absorption, distribution, metabolism, or excretion of the study drug, including impaired renal or hepatic function, diabetes mellitus, cardiovascular abnormalities, chronic symptoms of pronounced constipation or diarrhoea or conditions associated with total or partial obstruction of the urinary tract;
- •8.Having undergone any major surgery during the 6 months prior to the first study drug administration;
- •9.Blood donation or significant blood loss ( more or equal to 500mL within 60 days prior to the first study drug administration;
- •10.Plasma donation within 7 days prior to the first study drug administration;
- •11.Fever (body temperature more than 38°C) or symptomatic viral or bacterial infection within 2 weeks prior to Screening;
- •12.Any acute illness within 30 days prior to Day 0;
- •13.History of severe allergic or anaphylactic reactions;
- •14.Presence or history of allergies requiring acute or chronic treatment (except seasonal allergic rhinitis).
- •15.History of malignancy except for non-melanoma skin cancer excised more than 2 years prior to Screening;
- •16.Abnormal ECG findings at Screening including PR more or equal to 220 msec, QRS more ore equal to 120 msec, and Fridericia's correction more than 450 msec or ST wave changes or any other abnormal findings that are considered by the Investigator to be clinically significant,
- •17.History or presence of a condition associated with significant immunosuppression;
- •18.History of life-threatening infection (e.g. meningitis);
- •19.Infections requiring parenteral antibiotics within the 1 month prior to Screening;
- •20.Exposure to any significantly immune suppressing drug (including experimental therapies as part of a clinical trial) within the 4 months prior to Screening or 5-half-lives, whichever is longer;
- •21.Positive test for hepatitis C HCV virus antibody, hepatitis B surface antigen (HBsAg), or human immunodeficiency virus (HIV) antibody at Screening;
- •22.Participants with a positive urine drug screen test (including: cotinine, amphetamines, methamphetamines, phencyclidine, barbiturate, methadone, tricyclic antidepressant, cocaine, opiates, cannabinoids and benzodiazepines), and alcohol breath test;
- •23.Participants with a history of substance abuse or dependency or history of recreational intravenous (IV) drug use over the last 5 years (by self-declaration);
- •24.Regular alcohol consumption defined as more than 21 alcohol units per week (where 1 unit = 284 mL of beer, 25 mL of 40% spirit or a 125 mL glass of wine). Participant is unwilling to abstain from alcohol beginning 48 hours prior to admission to the CRU and during the confinement period;
- •25.Regular consumption of stimulat
研究者
相似试验
招募中
1 期
A First-in-Human Study of a Controlled Release Formulation of Lanreotide acetate in healthy male volunteersNeuroendocrine TumoursMetabolic and Endocrine - Other endocrine disordersCancer - Neuroendocrine tumour (NET)AcromegalyACTRN12620001261909Ascil Australia Pty LTD16
招募中
1 期
A Phase I study to evaluate the Pharmacokinetics and Safety of Letrozole LEBE in Healthy Post-menopausal Women.CTIS2023-503948-13-00aboratorios Farmaceuticos Rovi S.A.90
已完成
1 期
A Phase 1 Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Selgantolimod upon Co-administration with a Representative Proton Pump Inhibitor or H2-Receptor AntagonistHepatitis BOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonInfection - Other infectious diseasesACTRN12620001019998Gilead Sciences50
进行中（未招募）
不适用
Safety and Tolerability of Ceftazidime-Avibactam for pediatric patients with suspected or confirmed infectionshospitalized pediatric patients receiving systemic antibiotic therapy for suspected or confirmed infection.MedDRA version: 14.1Level: LLTClassification code 10021804Term: Infection bacterialSystem Organ Class: 100000004862EUCTR2013-001900-13-Outside-EU/EEAAstraZeneca AB32
已完成
1 期
A Phase 1 Study of AP02 (Nintedanib Solution for Inhalation) Delivered via the PARI eFlow®Nebulizer System in Healthy Volunteers and Patients with Idiopathic Pulmonary Fibrosis orProgressive Fibrosing Interstitial Lung DiseaseProgressive, Fibrosing Interstitial Lung DiseasesRespiratory - Other respiratory disorders / diseasesIdiopathic Pulmonary FibrosisACTRN12620001141932Avalyn Pharma Pty Ltd38